Mycobacterium tuberculosis Enfeksiyonu Öyküsü Olan Hastada Başarılı Bir Şekilde Nilotinibe Geçilen İmatinib ile Uyarılmış İnterstisyel Pnömonitis

Kaynakça (8)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037
2. Delomas T, Darne C, Besson C. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib. Leuk Lymphoma 2012;53:332-333
3. Dao K, Vedy D, Lopez J, Staneczek O, Buclin T, Livio F. Imatinib-induced dosedependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data. Int J Hematol 2013;97:299-300
4. Lee NR, Jang JW, Kim HS, Yhim HY. Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection. Korean J Intern Med 2015;30:550-553
5. Eşkazan AE, Salihoğlu A, Erturan S, Soysal T. Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turk J Hematol 2013;30:435-436
6. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-1164
7. Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, BruzzoniGiovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-818
8. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.